Trends in Dealmaking, Fundraising, and Partnerships:
The Changing Landscape

What is the webinar about?

The BIO International Convention brings together 16,000+ attendees across 1100+ biotech and pharma organizations for a week of networking, learning, new opportunities, and promising partnerships. Do you have the necessary information to pursue the best commercialization strategy for your asset?
Clarivate Analytics, BioWorld and BIO have teamed up to offer a free webinar to take a closer look at biotech investment and the changes that are opening more options for asset investment. Our webinar takes a look back at investment trends of 2017 and the shifting landscape that now includes strong optionality between deals, partnering, and fundraising.


Richard Harrison
Chief Scientific Officer
Clarivate Analytics

Dr. Richard K. Harrison is the Chief Scientific Officer at Clarivate Analytics. He has over 30 years of experience in the life sciences industry. His career has focused on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects. He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities.

Peter Winter
Clarivate Analytics/BioWorld

Peter Winter is a seasoned science journalist based in Ottawa, Canada and has been writing about and analyzing the progress of the biotech industry since the early 1980s. He is editor of BioWorld Insight, a weekly news service that tracks the financial and business trends of the biopharmaceutical industry. He was the founder and editor of Canadian Biotech News, a weekly newsletter that served the industry for 20 years. He received his undergraduate degree from the University of London and is the recipient of the Science Journalism Laureate Award from Purdue University (2009).

Willie Reaves
Director, Partnering Products & Services
Biotechnology Innovation Organization (BIO)

Willie directs product development for the BIO One-on-One Partnering™ system, a software platform that enables over 50,000 business meetings per year between biotech and pharmaceutical companies, investors, and others in the life science community He leads partnering strategy for BIO’s global portfolio of business development & licensing events across North America, Latin America, and Asia. Prior to joining BIO, Willie was a project manager in South Korea and Argentina and worked with the Patent Group at the Emory University Office of Technology Transfer.

Event details

  • Date Wednesday, May 9, 2018
  • Time 11 AM EDT  | 8 AM PDT  |  4 PM BST
  • Location WebEx login details sent after registration

Program Information

2017 was a strong year for biotech IPOs, putting the sell side companies in a favorable position of deciding between staying independent with public markets financing or selling to pharma. A strong IPO market can impact deals being made, as companies with options have more leverage to push toward higher valuations. What will the impact of biotech IPOs be in 2018? Will the optionality continue and drive asset values higher? An understanding of the investment options for an asset are an important part of the intelligence needed to target and plan successful meetings, and best practices for partnering will also be covered.

What topics will be discussed?

  • Review of 2017 deals and portfolio activity in BioPharma
  • IPO activity and a look at their impact in 2018
  • Getting ready for BIO with best practices for partnering success
  • Closing and Q&A